Developing new radiotracers

ESMO 2017 highlights on managing difficult to treat cancers

ESMO 2017 roundup with Dr Bishal Gyawali (1/2)

Pembrolizumab falls short of endpoints in KEYNOTE 40

ARIEL3: Rucaparib as maintenance therapy in recurrent ovarian cancer patients

Patient empowerment and quality of life

Chemoradiation remains best treatment for locally advanced cervical cancer

Fertility-preserving procedures in BRCA mutation-positive breast cancer

Biological insight in new drug combinations

BRIM8: Vemurafenib in high risk melanoma patients

Durvalumab in novel combinations for head and neck cancer

COMBI-AD: Dabrafenib plus trametinib in advanced melanoma